Business Context and Reporting Period
This Form 8-K Current Report is filed by Elevai Labs Inc. (not PMGC Holdings Inc. as indicated in metadata) for the reporting period ending June 20, 2024. The registrant is an emerging growth company incorporated in Delaware, with common stock trading on The Nasdaq Stock Market under the symbol ELAB. The filing primarily addresses significant changes in executive leadership and corporate governance.
Key Financial Metrics
This filing does not contain audited financial statements, revenue, profit, cash flow, or debt metrics. The only financial data disclosed relates to executive compensation arrangements:
- Graydon Bensler (New CEO): Annual compensation of $200,000 under an amended consulting agreement with GB Capital Ltd.
- Braeden Lichti (New Non-Executive Chairman): Annual compensation of $199,200 under an amended consulting agreement with NorthStrive Companies Inc.
Material Changes Versus Prior Period
The filing details a major restructuring of the Company's executive team effective June 21, 2024:
- Resignation of CEO: Dr. Jordan Plews resigned as Chief Executive Officer. His resignation was not due to any dispute with the Board. He will retain his role as CEO of the subsidiaries Elevai Skincare, Inc. and Elevai Biosciences, Inc.
- Terminations: Brenda Buechler (Chief Marketing Officer) and Christoph Kraneiss (Chief Commercial Officer) were involuntarily terminated without cause as part of a reduction in force to streamline operations. The Company does not intend to fill these roles immediately.
- Appointment of Non-Employee CEO: Graydon Bensler, previously the Chief Financial Officer and Director, was appointed as the new non-employee Chief Executive Officer. He will continue as CFO until a successor is identified.
- Appointment of Chairman: Braeden Lichti, a co-founder and strategic consultant since 2020, was appointed as Non-Executive Chairman and Director. This appointment required the termination of his prior advisory agreement dated February 1, 2023.
Guidance, Outlook, and Risks
Management Commentary: The leadership changes are part of a strategy to streamline operations and organizational structure. The Board believes Mr. Lichti's network in banking, biotech, and healthcare, along with his experience in restructuring, will be an asset to the Company.
Risks and Contingencies: The filing notes the involuntary termination of two senior officers and the transition to a non-employee CEO. No specific financial risks or contingencies regarding liquidity or debt are disclosed in this document.
Investor Verification Checklist
- Verify the impact of the CEO transition from an employee (Dr. Plews) to a non-employee consultant (Mr. Bensler) on daily operations.
- Confirm the status of the eliminated roles (CMO and CCO) and whether interim coverage is in place.
- Review the attached Exhibits 10.1 through 10.4 for detailed terms of the new consulting agreements and the termination of the prior advisory agreement.
- Monitor future filings for the appointment of a permanent CFO to replace Mr. Bensler in that role.